B-Cell chronic lymphocytic leukemia

From Citizendium, the Citizens' Compendium

Jump to: navigation, search


This article is a stub and thus not approved.
Main Article
Talk
Related Articles  [?]
Bibliography  [?]
External Links  [?]
 
This is a draft article, under development and not meant to be cited but you can help to improve it. These unapproved articles are subject to a disclaimer.

In medicine, B-Cell chronic lymphocytic leukemia, also called chronic lymphocytic leukemia (CLL), is a "chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease."[1][2][3]

Contents

Prognosis

5-Year Relative Survival Rates By Year Dx By Leukemia type All Ages, All Races, Both Sexes 1975-2000.
5-Year Relative Survival Rates By Year Dx By Leukemia type All Ages, All Races, Both Sexes 1975-2000.

Staging information

B-Cell chronic lymphocytic leukemia staging information from the National Cancer Institute's Physician Data Query


Treatment

B-Cell chronic lymphocytic leukemia treatment information from the National Cancer Institute's Physician Data Query


As a primary antineoplastic agent, fludarabine may be more effective than chlorambucil.[4]


Treatment options for Stage I, II, III, and IV CLL[5]
Regimen Effectiveness Adverse effects
Combination:[6][7]
• Fludarabine
• Cyclophosphamide
• Rituximab
Complete remission in 25% to 72% • Neutropenia
• 10% rate of infection during first year
• Rituximab induced fever (37%), chills (50%), hypotension (13%), nausea and vomiting

References

  1. Anonymous, (2009) B-Cell chronic lymphocytic leukemia (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE (September 2006). Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann. Intern. Med. 145 (6): 435–47. PMID 16983131.
  3. Chiorazzi N, Rai KR, Ferrarini M (February 2005). Chronic lymphocytic leukemia. N. Engl. J. Med. 352 (8): 804–15. DOI:10.1056/NEJMra041720. PMID 15728813.
  4. Rai KR, Peterson BL, Appelbaum FR, et al (December 2000). Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343 (24): 1750–7. PMID 11114313.
  5. Anonymous. Chronic Lymphocytic Leukemia Treatment -. National Cancer Institute. Retrieved on 2009-03-31.
  6. Wierda W, O'Brien S, Wen S, et al (June 2005). Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 23 (18): 4070–8. DOI:10.1200/JCO.2005.12.516. PMID 15767647. Retrieved on 2009-03-31.
  7. Tam CS, O'Brien S, Wierda W, et al (August 2008). "Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia". Blood 112 (4): 975–80. DOI:10.1182/blood-2008-02-140582. PMID 18411418. Retrieved on 2009-03-31.
Views
Personal tools